(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 13.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.01%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Apellis Pharmaceuticals's revenue in 2025 is $775,840,000.On average, 10 Wall Street analysts forecast APLS's revenue for 2025 to be $107,870,318,748, with the lowest APLS revenue forecast at $92,891,758,366, and the highest APLS revenue forecast at $133,303,632,246. On average, 10 Wall Street analysts forecast APLS's revenue for 2026 to be $117,862,184,101, with the lowest APLS revenue forecast at $96,454,850,437, and the highest APLS revenue forecast at $131,329,163,942.
In 2027, APLS is forecast to generate $145,666,619,116 in revenue, with the lowest revenue forecast at $129,309,450,024 and the highest revenue forecast at $161,560,774,762.